NCT05880927View on ClinicalTrials.gov

Pyrotinib After Trastuzumab-based Adjuvant Therapy in Patients With HER2-positive Breast Cancer

PHASE2RecruitingINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

January 1, 2019

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions

Breast Cancer

Interventions

DRUG

Pyrotinib

Patients receive pyrotinib 400mg/day for half or one year

Trial Locations (1)

Unknown

RECRUITING

Taizhou Hospital, Taizhou

All Listed Sponsors

lead

Taizhou Hospital

OTHER